Table 2 Developed metallic DES with durable polymers for coronary arteries [17]
From: Analysis of trends and prospects regarding stents for human blood vessels
Stent | Manufacturer | Drug (Dose: μg/mm2) | Polymer | Polymer Thickness (μm) | Stent Platform | Strut Thickness (μm) |
|---|---|---|---|---|---|---|
Cypher | Cordls Corporation | Sirolimus (1.4) | PEVA+PBMA | 12.6 | SS | 140 |
Cypher select | Cordls Corporation | Sirolimus | PEVA+PBMA | N/A | SS | 100 |
Elixir Myolimus | Elixir Medical | Myolimus (40 μg) | Methacrylate | < 3 | CoCr | N/A |
Endeavor | Medtronic, Inc. | Zotarolimus (10) | Phosphorylcholine | 5.3 | CoCr | 91 |
Excella | Elixir Medical Corporation | Novolimus (0.85) | Methacrylate | 3 | CoCr | 81 |
Promus | Boston Scientific Corporation | Everolimus (1) | Fluoropolymer | 7.6 | CoCr | 81 |
Taxus Express | Boston Scientific Corporation | Paclitaxel (1) | SIBS (Translute) | 16 | SS | 132 |
Taxus Liberte | Boston Scientific Corporation | Paclitaxel (1) | SIBS (Translute) | 16 | SS | 97 |
Taxus Petal | Boston Scientific Corporation | Paclitaxel | SIBS (Translute) | N/A | Platinum Chromium | N/A |
Xience V | Abbott Vascular | Everolimus (1) | Fluoropolymer | 7.6 | CoCr | 81 |
ZoMaxx | Abbott Vascular | Zotarolimus (10) | Phosphorylcholine | 5 | SS/Tantalum | 74 |